Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
jRCT2031210310Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of surufatinib in Non-hematologic malignancy, apudoma (NET), islet cell tumor and 1 more (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Safety endpoints (Part 1) and Objective response rate (ORR) (Part 2). Started Sep 2021; status: completed.
02
Drugs
surufatinib
03
Conditions
Non-hematologic malignancyapudoma (NET)islet cell tumorNeuroendocrine tumor (NET)
Beyond the preview
Go deeper on jRCT2031210310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210310.